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Current Limitations for Investigating 
Marfan Syndrome
• Previous murine models can take years to develop a 
mild aortopathy
• Cardiomyopathies are rare and inconsistent 
• Losartan alone does not completely attenuate aortic 
aneurysm formation, suggesting a need for multi-modal 
treatment and alternate signaling pathways must be 
elucidated.
Development of Marfan Syndrome Murine Model
• B6.129 (Wild-type) and Fbn1C1039G/+ (MFS) 
• Creation of an accelerated MFS-induced cardiomyopathy 
via subcutaneous osmotic mini-pump installation for 14 
days in 3 treatment groups: Wild-type + 0.9% saline 
(vehicle); MFS + vehicle; MFS + angiotensin II 
(4.5mg/kg/day) (accelerated treatment group).
• Wild-type + Angiotensin II was insignificantly different from 
our vehicle.
Does the model really work…
Accelerated MFS Model Phenotype
• Aortic diameter nearly doubles
• Over half of MFS + Ang II mice are deceased at 28 days 
Aortic Verhoeff–Van Gieson stain
• Elastin (black) is blindly 
scored, ranking 1 (no 
breaks) to 4 (highly 
fractionated)
• Note increase in adventitia 
in MFS + Angiotensin II
Presence of Cardiomyopathy
Cardiomyopathy with Respect to 
Aortic Insufficiency
Intrinsic Cardiomyopathy
• Ejection fraction <80% and an indexed left ventricular end 
diastolic volume >1.75 μl/g.
• No dilated cardiomyopathies in wild-type mice
• 60% of surviving accelerated MFS mice revealed dilated 
cardiomyopathies at 14 days. 
• Just under half of the cardiomyopathic accelerated MFS 
mice occurred in the presence of either none or mild aortic 
insufficiency.
Cardiac Hematoxylin & Eosin Stain
• Cross sectional stains are taken from left ventricle
• Vehicle cells are mononucleated, while MFS + Ang II are 
polynucleated and muscle fibers are distended
Relevance of Transient Receptor Potential Channels
• Members of the family of transient receptor potential 
channels (TRP) have emerged as likely regulators of VSMC 
activity. 
• Additionally, newer research suggests TRP channels may 
regulate various forms of cardiomyopathy.
Aortic Expression in Murine MFS Model
• TRPC4 demonstrated a 
9.9 fold increase at DNA level
• TRPC4 demonstrated a 
7.2 fold increase at protein level 
• Aortic tissue is not of quality 
RNA Integrity to utilize in RNA-
seq 
Cardiac Expression in Murine MFS Model
• TRPC6 demonstrated a 
2-fold increase at the DNA 
level
• TRPC6 demonstrated a 
5-fold increase at protein 
level 
Cardiac RNA Expression in Murine MFS Model
• FPKM should be thought of as comparable to # of reads
• TRPC6 demonstrated a 1.7 fold increase at RNA level
Current Studies
• We are investigating multiple signaling cascades that 
delineate the role of TRPC4 in aneurysm formation and 
TRPC6 in a MFS-induced cardiomyopathy.
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